Linked Life Data

15455372

Source:http://linkedlifedata.com/resource/pubmed/id/15455372

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15455372rdf:typepubmed:Citationlld:pubmed
pubmed-article:15455372lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:15455372lifeskim:mentionsumls-concept:C0389003lld:lifeskim
pubmed-article:15455372lifeskim:mentionsumls-concept:C1565860lld:lifeskim
pubmed-article:15455372lifeskim:mentionsumls-concept:C1705323lld:lifeskim
pubmed-article:15455372lifeskim:mentionsumls-concept:C0600139lld:lifeskim
pubmed-article:15455372lifeskim:mentionsumls-concept:C1518174lld:lifeskim
pubmed-article:15455372lifeskim:mentionsumls-concept:C1704263lld:lifeskim
pubmed-article:15455372lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:15455372lifeskim:mentionsumls-concept:C0059438lld:lifeskim
pubmed-article:15455372lifeskim:mentionsumls-concept:C0392760lld:lifeskim
pubmed-article:15455372lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:15455372lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:15455372pubmed:issue4lld:pubmed
pubmed-article:15455372pubmed:dateCreated2004-12-7lld:pubmed
pubmed-article:15455372pubmed:abstractTextOverexpression of cyclooxygenase (COX)-2 has been implicated in many pathologic conditions, including cancer. One practical inference of this finding is that sustained inhibition of COX-2 could serve as a promising target for prevention or therapy of cancer. Conventional nonsteroidal antiinflammatory drugs (NSAIDs) and recently developed COX-2-specific inhibitors have shown considerable promise in prevention of some forms of human cancer; however, its application is limited due to severe toxic side effects on normal cells. Therefore, there is a need to define novel, nontoxic dietary constituents with proven chemopreventive effects through other pathways that also possess COX-2 but not COX-1 inhibitory activity. Recent studies on green tea and its major polyphenolic constituent (-)epigallocatechin-3-gallate (EGCG) have established its remarkable cancer preventive and some cancer therapeutic effects. Here, we show that EGCG inhibits COX-2 without affecting COX-1 expression at both the mRNA and protein levels, in androgen-sensitive LNCaP and androgen-insensitive PC-3 human prostate carcinoma cells. Based on our study, it is tempting to suggest that a combination of EGCG with chemotherapeutic drugs could be an improved strategy for prevention and treatment of prostate cancer.lld:pubmed
pubmed-article:15455372pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:languageenglld:pubmed
pubmed-article:15455372pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:citationSubsetIMlld:pubmed
pubmed-article:15455372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15455372pubmed:statusMEDLINElld:pubmed
pubmed-article:15455372pubmed:monthFeblld:pubmed
pubmed-article:15455372pubmed:issn0020-7136lld:pubmed
pubmed-article:15455372pubmed:authorpubmed-author:GuptaSanjaySlld:pubmed
pubmed-article:15455372pubmed:authorpubmed-author:AdhamiVaqar...lld:pubmed
pubmed-article:15455372pubmed:authorpubmed-author:MukhtarHasanHlld:pubmed
pubmed-article:15455372pubmed:authorpubmed-author:HussainTajamu...lld:pubmed
pubmed-article:15455372pubmed:issnTypePrintlld:pubmed
pubmed-article:15455372pubmed:day10lld:pubmed
pubmed-article:15455372pubmed:volume113lld:pubmed
pubmed-article:15455372pubmed:ownerNLMlld:pubmed
pubmed-article:15455372pubmed:authorsCompleteYlld:pubmed
pubmed-article:15455372pubmed:pagination660-9lld:pubmed
pubmed-article:15455372pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:meshHeadingpubmed-meshheading:15455372...lld:pubmed
pubmed-article:15455372pubmed:year2005lld:pubmed
pubmed-article:15455372pubmed:articleTitleGreen tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells.lld:pubmed
pubmed-article:15455372pubmed:affiliationUniversity of Wisconsin, Department of Dermatology, 1300 University Ave., Madison, WI 53706, USA.lld:pubmed
pubmed-article:15455372pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15455372pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:15455372pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:15455372pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15455372lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15455372lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15455372lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15455372lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15455372lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15455372lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15455372lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15455372lld:pubmed